Roche Expands U.S. Operations with $50 Billion Strategic Investment
Introduction:
Roche has announced a major investment of USD 50 billion in the United States, aimed at expanding its presence nationwide. This move will strengthen Roche’s already substantial footprint in the U.S., which currently includes 13 manufacturing sites and 15 R&D facilities across its Pharmaceuticals and Diagnostics divisions.
Features:
Expanding and upgrading manufacturing and distribution facilities in Kentucky, Indiana, New Jersey, Oregon, and California to support its pharmaceutical and diagnostics portfolio.
Establishing a gene therapy manufacturing site in Pennsylvania.
Constructing a new 900,000-square-foot facility for the production of next-generation weight loss medicines.
Setting up a new research and development centre in Massachusetts, with a focus on artificial intelligence and research in cardiovascular, renal, and metabolic diseases.
Enhancing pharmaceutical and diagnostics R&D operations in Arizona, Indiana, and California.
The Project will be completed by 2030.
Specifications:
Name : Roche
Budget : USD 50 Billion
Type : Construction & Expansion
Year : 2030
